IRIS
PISANI, ANTONIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 8.978
AS - Asia 8.959
EU - Europa 6.176
SA - Sud America 1.083
Continente sconosciuto - Info sul continente non disponibili 452
AF - Africa 251
OC - Oceania 11
AN - Antartide 1
Totale 25.911
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.581
SG - Singapore 3.946
RU - Federazione Russa 2.661
VN - Vietnam 1.737
CN - Cina 1.679
IT - Italia 1.569
BR - Brasile 820
HK - Hong Kong 644
FR - Francia 358
DE - Germania 352
FI - Finlandia 221
CA - Canada 218
GB - Regno Unito 169
BD - Bangladesh 160
UA - Ucraina 160
IN - India 154
IE - Irlanda 142
NL - Olanda 141
JP - Giappone 128
AR - Argentina 107
MX - Messico 103
SE - Svezia 77
PL - Polonia 67
ZA - Sudafrica 67
IQ - Iraq 66
CI - Costa d'Avorio 62
KR - Corea 57
RO - Romania 51
EC - Ecuador 46
PH - Filippine 39
TR - Turchia 38
ID - Indonesia 36
TH - Thailandia 34
CO - Colombia 30
ES - Italia 29
PK - Pakistan 29
AT - Austria 27
TW - Taiwan 24
VE - Venezuela 24
MK - Macedonia 23
EG - Egitto 20
MY - Malesia 20
IR - Iran 18
KE - Kenya 18
UZ - Uzbekistan 18
BE - Belgio 17
NP - Nepal 16
JM - Giamaica 15
MA - Marocco 15
LT - Lituania 14
TN - Tunisia 14
JO - Giordania 13
CL - Cile 12
IL - Israele 12
PE - Perù 12
RS - Serbia 12
UY - Uruguay 12
BG - Bulgaria 11
CH - Svizzera 10
DZ - Algeria 10
PY - Paraguay 10
SA - Arabia Saudita 10
CR - Costa Rica 9
HN - Honduras 9
KZ - Kazakistan 9
AE - Emirati Arabi Uniti 8
ET - Etiopia 8
GR - Grecia 8
KG - Kirghizistan 8
BO - Bolivia 7
AU - Australia 6
BB - Barbados 6
KH - Cambogia 6
PT - Portogallo 6
CZ - Repubblica Ceca 5
DO - Repubblica Dominicana 5
MN - Mongolia 5
NI - Nicaragua 5
SI - Slovenia 5
TT - Trinidad e Tobago 5
AO - Angola 4
AZ - Azerbaigian 4
BH - Bahrain 4
BJ - Benin 4
CY - Cipro 4
EE - Estonia 4
EU - Europa 4
GE - Georgia 4
GT - Guatemala 4
HR - Croazia 4
LV - Lettonia 4
NG - Nigeria 4
NO - Norvegia 4
OM - Oman 4
PS - Palestinian Territory 4
QA - Qatar 4
SK - Slovacchia (Repubblica Slovacca) 4
SN - Senegal 4
SY - Repubblica araba siriana 4
AL - Albania 3
Totale 25.384
Salva come PNG Salva come JPEG
Città #
Singapore 1.765
San Jose 1.329
Ashburn 700
Moscow 667
Hong Kong 607
Chandler 555
Beijing 506
Ho Chi Minh City 433
Hanoi 356
Santa Clara 350
Los Angeles 236
Napoli 236
Hefei 231
Millbury 217
Lauterbourg 208
Naples 189
The Dalles 175
Princeton 157
Nanjing 147
Dong Ket 142
Boston 140
New York 134
Council Bluffs 126
Jacksonville 124
Tokyo 110
Buffalo 101
Des Moines 99
Wilmington 97
Rome 90
São Paulo 90
Da Nang 88
Munich 88
Amsterdam 85
Milan 84
Redondo Beach 80
Haiphong 66
Orem 65
Dublin 64
Dallas 63
Ottawa 62
Lawrence 56
Frankfurt am Main 54
Warsaw 52
Montreal 50
Bucharest 46
Mexico City 46
Seattle 46
Atlanta 41
Helsinki 41
Nanchang 41
Denver 40
Brooklyn 39
Caserta 38
Houston 38
Nuremberg 36
Toronto 36
Seoul 35
Chicago 34
Johannesburg 34
Chennai 33
Hải Dương 33
Poplar 31
Rio de Janeiro 31
Shenyang 31
Stockholm 31
Phoenix 30
Tianjin 29
Baghdad 28
Buenos Aires 28
Hebei 28
London 28
San Francisco 28
Turku 26
Washington 25
Biên Hòa 24
Boardman 24
Falkenstein 21
Woodbridge 21
Can Tho 20
Redwood City 20
Norwalk 19
Augusta 17
Brasília 17
Jiaxing 17
Manchester 17
Ninh Bình 17
Bangkok 16
Florence 16
Nairobi 16
New Delhi 16
Shanghai 16
Mumbai 15
Querétaro 15
Quito 15
Tashkent 15
Changsha 14
Turin 14
Vienna 14
Amman 13
Bari 13
Totale 12.747
Salva come PNG Salva come JPEG
Nome #
Il nefrologo nel trattamento dell’iperammoniemia da disordini del ciclo dell’urea 609
Polimirfismo del gene dell'ACE ed eritrocitosi nel trapianto di rene 463
Late diagnosis of Fabry disease caused by a de novo mutation in a patient with end stage renal disease Case Reports 308
Liposomial iron: a new proposal for the treatment of anaemia in chronic kidney disease 289
Endocrine dysfunction in patients with Fabry disease 196
Corpus callosum involvement: a useful clue for differentiating Fabry Disease from Multiple Sclerosis 192
Effect of a Short-Course Treatment with Synbiotics on Plasma p-Cresol Concentration in Kidney Transplant Recipients. 192
Experimental evidence and clinical implications of Warburg effect in the skeletal muscle of Fabry disease 190
Aortopathies in mouse models of Pompe, Fabry and Mucopolysaccharidosis IIIB lysosomal storage diseases 188
Alterations of functional connectivity of the motor cortex in Fabry disease: An RS-fMRI study 175
Diagnostic, Predictive, Prognostic, and Therapeutic Molecular Biomarkers in Third Millennium: A Breakthrough in Gastric Cancer 165
EC-MPS permits lower gastrointestinal symptom burden despite higher MPA exposure in patients with severe MMF-related gastrointestinal side-effects. 163
Plasma p-cresol lowering effect of sevelamer in non-dialysis CKD patients: evidence from a randomized controlled trial 161
Reversal of radiocontrast medium toxicity in human renal proximal tubular cells by white grape juice extract 160
Pituitary function and morphology in Fabry disease. 159
Real-world management of chronic and postprandial hyperkalemia in CKD patients treated with patiromer: a single-center retrospective study 158
Cardiopulmonary determinants of reduced exercise tolerance in Fabry disease 155
Striatonigral involvement in Fabry Disease: A quantitative and volumetric Magnetic Resonance Imaging study 154
6-tips diet: a simplified dietary approach in patients with chronic renal disease. A clinical randomized trial 153
Current tissue molecular markers in colorectal cancer: A literature review 152
Nutritional management in renal transplant recipients: A transplant team opportunity to improve graft survival 152
RAAS Inhibitor Prescription and Hyperkalemia Event in Patients With Chronic Kidney Disease: A Single-Center Retrospective Study 151
Parapelvic cysts, a distinguishing feature of renal Fabry Disease. 150
Immunosuppression and multiple primary malignancies in kidney transplanted patients. A single-institute study 149
Cerebrovascular and Brain Abnormalities In Autosomal-Dominant Polycystic Kidney Disease: Role Of 3d Time-of-Flight Magnetic Resonance Angiography 149
Absence of infratentorial lesions in Fabry disease contributes to differential diagnosis with multiple sclerosis 149
Hybrid positron emission tomography-magnetic resonance imaging for assessing different stages of cardiac impairment in patients with Anderson-Fabry disease: AFFINITY study group 147
Atorvastatin improves the course of ischemic acute renal failure in aging rats 147
Effect of paricalcitol vs calcitriol on hemoglobin levels in chronic kidney disease patients: a randomized trial 147
Renal sympathetic-nerve ablation for uncontrolled hypertension in a patient with single-kidney autosomal dominant polycystic kidney disease. 146
Relationship between left ventricular diastolic function and myocardial sympathetic denervation measured by (123)I-meta-iodobenzylguanidine imaging in Anderson-Fabry disease 145
The effects of somatostatin analogues on liver volume and quality of life in polycystic liver disease: a meta-analysis of randomized controlled trials 145
Parapelvic Cysts: An Imaging Marker of Kidney Disease Potentially Leading to the Diagnosis of Treatable Rare Genetic Disorders? A Narrative Review of the Literature 144
Bowel obstruction and peritoneal carcinomatosis in the elderly. A systematic review 144
Effect of oral liposomal iron versus intravenous iron for treatment of iron deficiency anaemia in CKD patients: A randomized trial 144
Reduced intracranial volume in Fabry Disease: Evidence of abnormal neurodevelopment? 144
The central vein sign helps in differentiating multiple sclerosis from its mimickers: lessons from Fabry disease 143
Molecular Mechanisms of Renal Cellular Nephrotoxicity due to Radiocontrast Media 143
A strange epigastric pain. 143
C5 Convertase Blockade in Membranoproliferative Glomerulonephritis: A Single-Arm Clinical Trial 143
Identifying Fabry patients in dialysis population: prevalence of GLA mutations by renal clinic screening, 1995–2019 143
Default mode network modifications in Fabry disease: A resting-state fMRI study with structural correlations 140
Early Biomarkers of Fabry Nephropathy: A Review of the Literature. 138
Effects of switching from agalsidase Beta to agalsidase alfa in 10 patients with anderson-fabry disease. 137
Oral Sucrosomial® iron versus intravenous iron for recovering iron deficiency anaemia in ND-CKD patients: a cost- minimization analysis. 137
Long-term Effects of Octreotide on Liver Volume in Patients With Polycystic Kidney and Liver Disease 136
A novel GLA mutation in a Fabry family with glucose-6-phosphate dehydrogenase deficiency 134
Endothelial-mediated coronary flow reserve in patients with Anderson-Fabry disease 133
Prevalence of GLA gene mutations and polymorphisms in patients with multiple sclerosis: A cross-sectional study 133
Neuroimaging in Fabry disease: current knowledge and future directions 133
Advanced CMR Techniques in Anderson-Fabry Disease: State of the Art 132
Thyroid function in Fabry disease before and after enzyme replacement therapy. 132
Genetic variants associated with gastrointestinal symptoms in Fabry disease. 131
Fatigue as hallmark of Fabry disease: role of bioenergetic alterations 130
Arginase inhibition slows the progression of renal failure in rats with renal ablation 130
Prominent longitudinal strain reduction of left ventricular basal segments in treatment-naïve Anderson-Fabry disease patients 130
Optical Coherence Tomography Angiography Findings in Fabry Disease 130
Familial polycystic kidneys with no genetic confirmation: Are we sure it is ADPKD? 129
Increased Expression of Orexin-A in Patients Affected by Polycystic Kidney Disease 128
Motor involvement in Fabry disease 128
ADPKD and metformin: from bench to bedside 128
Ketogenic diet in ADPKD patient 128
Agalsidase therapy in patients with Fabry disease on renal replacement therapy: a nationwide study in Italy. 127
Insomnia in maintenance haemodialysis patients. 125
Cardiac performance during exercise in patients with Fabry's disease 125
Prognostic Implications of the Extent of Cardiac Damage in Patients With Fabry Disease 124
Antiproteinuric effect of add-on paricalcitol in Fabry disease patients: a prospective observational study. 124
An unusual case of tuberous sclerosis incidentally discovered in adulthood: case report and review of the literature 124
Stepwise shortening of agalsidase beta infusion duration in Fabry disease: Clinical experience with infusion rate escalation protocol 124
Methylome Profiling in Fabry Disease in Clinical Practice: A Proof of Concept 124
Clinical manifestation of patients with Fabry disease and R356W GLA variant 123
Metabolic effects of two low protein diets in chronic kidney disease stage 4-5--a randomized controlled trial. 123
Role of cardiac MRI in evaluating patients with Anderson-Fabry disease: assessing cardiac effects of long-term enzyme replacement therapy. 123
The Choice of the Iodinated Radiographic Contrast Media to Prevent Contrast-Induced Nephropathy 122
Early Cardiac Involvement Affects Left Ventricular Longitudinal Function in Females Carrying α-Galactosidase A Mutation: Role of Hybrid Positron Emission Tomography and Magnetic Resonance Imaging and Speckle-Tracking Echocardiography 122
Assessing brain involvement in Fabry disease with deep learning and the brain‐age paradigm 121
Prevention of contrast-induced nephropathy through a knowledge of its pathogenesis and risk factors 121
Home infusion program with enzyme replacement therapy for Fabry disease: The experience of a large Italian collaborative group 121
Randomized Controlled Trials on Renin Angiotensin Aldosterone System Inhibitors in Chronic Kidney Disease Stages 3-5: Are They Robust? A Fragility Index Analysis 120
Ultra-deep dna methylation analysis of x-linked genes: Gla and ar as model genes [*De Riso G., Cuomo M co-primi autori] 120
Therapeutic advances in ADPKD: the future awaits 120
Layer-specific longitudinal strain in Anderson–Fabry disease at diagnosis: A speckle tracking echocardiography analysis 119
Visceral Leishmaniasis in renal transplant recipients. Is it still a challange to the Nephrologist? 118
Atrial septum aneurysm: an unusual manifestation in ADPKD? 117
Terapia enzimatica sostitutiva nella malattia di Fabry: cosa abbiamo imparato dallo switch? 117
Molecular and clinical studies in five index cases with novel mutations in the GLA gene. 117
Effects of valsartan, benazepril and their combination in overt nephropathy of type 2 diabetes: A prospective, randomized, controlled trial 117
Redefining the Pulvinar Sign in Fabry Disease 116
Author response: Alterations of functional connectivity of the motor cortex in Fabry disease: An RS-fMRI study 116
Effects of atorvastatin on renal function in patients with chronic renal failure. 115
Effect of a low- versus moderate-protein diet on progression of CKD: follow-up of a randomized controlled trial. 115
Fabry's disease: a comparison of the effectiveness of two different enzyme replacement therapies 115
Cardiovascular magnetic resonance native T1 mapping in Anderson-Fabry disease: a systematic review and meta-analysis 115
[Type I Hyperprolinemia - What about the Kidney?] 114
Tolvaptan vs. somatostatin in the treatment of ADPKD: A review of the literature 114
Mutations in the GLA gene and LysoGb3: Is it really Anderson-Fabry disease? 114
The role of immunosuppressive therapy in aneurysmal degeneration of hemodialysis fistulas in renal transplant patients: Aneurysmatic arteriovenous fistula in transplant patients 114
Agalsidase alfa and agalsidase beta in the treatment of Fabry disease: does the dose really matter? 113
Visceral Leishmaniasis in renal transplant recipients: is it still a challenge to the nephrologist? 113
Multimodality imaging approach to Fabry cardiomyopathy: Any role for nuclear cardiology? 113
Totale 14.752
Salva come PNG Salva come JPEG
Categoria #
all - tutte 84.679
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 84.679
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.162 0 4 11 13 15 37 37 52 112 109 261 511
2022/20231.347 222 125 50 119 144 147 19 126 221 79 73 22
2023/20241.190 56 276 107 62 69 112 24 102 27 25 247 83
2024/20256.013 339 317 38 110 124 369 631 345 505 626 2.082 527
2025/202612.711 1.399 920 1.195 1.233 2.218 523 1.370 781 1.278 915 548 331
2026/20271.048 728 320 0 0 0 0 0 0 0 0 0 0
Totale 25.911